|
|
 |
|
Viewing report
|
|
|
|
Novartis's Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape
GlobalData, Sep 2011, Pages: 6
Novartis’s Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape
Summary
GlobalData, the industry analysis specialist, has released its new report, “Novartis’s Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape”. The report is an essential source of information and analysis on irritable bowel syndrome (IBS) market. The report provides insights on the Zelnorm commercialization. Most importantly, the report provides valuable insights on the Zelnorm life cycle and its market revenues. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the NSCLC market. Its scope includes -
- Treatment options in IBS market and role Zelnorm.
- Zelnorm clinical trials and its overall market events.
- Market revenues of Zelnorm
- Events leading to market withdrawl of Zelnorm
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding the Zelnorm’s commercialization story
- Leverage the opportunity of branding with key markets having high market potential
- Formulate effective marketing strategies from the learnings of Zelnorm
- Organize your sales and marketing efforts by identifying the key competitors
|
|
|
|
